Abivax S.A. (ABVX)
NASDAQ: ABVX
· Real-Time Price · USD
95.63
1.86 (1.98%)
At close: Oct 13, 2025, 3:59 PM
95.08
-0.58%
Pre-market: Oct 14, 2025, 07:00 AM EDT
1.98% (1D)
| Bid | 95.4 |
| Market Cap | 7.22B |
| Revenue (ttm) | 9.42M |
| Net Income (ttm) | -195.39M |
| EPS (ttm) | -3.59 |
| PE Ratio (ttm) | -26.64 |
| Forward PE | -32 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 95.92 |
| Volume | 989,215 |
| Avg. Volume (20D) | 1,764,920 |
| Open | 97.00 |
| Previous Close | 93.77 |
| Day's Range | 93.43 - 97.04 |
| 52-Week Range | 4.77 - 97.83 |
| Beta | 0.10 |
| Ex-Dividend Date | n/a |
About ABVX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ABVX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ABVX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAbivax S.A. is scheduled to release its earnings on
Mar 23, 2026,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+3.28%
Abivax shares are trading higher after the company...
Unlock content with
Pro Subscription
2 months ago
+4.85%
Abivax shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $70 to $112.
2 months ago · seekingalpha.com
Abivax: Differentiated Phase 3 Data Ignites A Multi-Billion Dollar OpportunityObefazimod's strong Phase 3 induction data positions Abivax as a leading UC contender, with a novel mechanism and favorable safety profile. The ABTECT program's robust design and inclusion of hard-to-...
2 months ago · seekingalpha.com
Abivax: Good Entry Point Ahead Of The Mega Catalyst - Phase 3 Data ReadoutAbviax's Obefazimod shows promising phase 2b results in ulcerative colitis, with superior safety and efficacy compared to existing treatments, supporting a buy rating. The drug's novel mechanism modul...